enGene price target lowered to $34 from $37 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on enGene (ENGN) to $34 from $37 and keeps an Overweight rating on the shares after the company reported Q1 results and provided an update on the LEGEND study of detalimogene. The protocol changes disclosed should help detalimogene demonstrate better durability and further solidify the therapy’s risk/benefit profile for physicians and patients, the analyst tells investors.